ArticleInternational journal of clinical and experimental pathology2014
Epigallocatechin-3-gallate protects against cisplatin nephrotoxicity by inhibiting the apoptosis in mouse.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Functional, Structural and Genetic Modulation in Plasma and Renal Antioxidant Systems by Quercetin, Catechin and Genistein in Cisplatin-Induced Acute Nephrotoxicity in Wistar Rats.Food science & nutrition · 2025Article
- Khellin Mitigates Cisplatin-Induced Renal Injury by Targeting Oxidative Stress, Inflammation, and Apoptosis: Integration of Network Pharmacology, Molecular Docking, and Preclinical Validation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- MicroRNAs Involved in Intrinsic Apoptotic Pathway during Cisplatin-Induced Nephrotoxicity: Potential Use of Natural Products against DDP-Induced Apoptosis.Biomolecules · 2022Review
- Polyphenols and Their Metabolites in Renal Diseases: An Overview.Foods (Basel, Switzerland) · 2022Review
- Honokiol-camptothecin loaded graphene oxide nanoparticle towards combinatorial anti-cancer drug delivery.IET nanobiotechnology · 2020Article
- Isoliquiritigenin Pretreatment Induces Endoplasmic Reticulum Stress-Mediated Hormesis and Attenuates Cisplatin-Induced Oxidative Stress and Damage in LLC-PK1 Cells.Molecules (Basel, Switzerland) · 2020Article
- Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy.International journal of nanomedicine · 2020Article
- Renoprotective Effects of a New Free Radical Scavenger, XH-003, against Cisplatin-Induced Nephrotoxicity.Oxidative medicine and cellular longevity · 2020Article
- Molecular Mechanisms of Epigallocatechin-3-Gallate for Prevention of Chronic Kidney Disease and Renal Fibrosis: Preclinical Evidence.Current developments in nutrition · 2019Review
- Application of Herbal Traditional Chinese Medicine in the Treatment of Acute Kidney Injury.Frontiers in pharmacology · 2019Review
- Protective Effects of Epigallocatechin-3-Gallate from Green Tea in Various Kidney Diseases.Advances in nutrition (Bethesda, Md.) · 2019Article
- Prophylactic efficacy of some chemoprotectants against abrin induced lethality.Interdisciplinary toxicology · 2018Article
- Epigallocatechin-3-gallate counters cisplatin toxicity of rat testes.Pharmaceutical biology · 2017Article
- Resveratrol attenuates acute kidney injury by inhibiting death receptor‑mediated apoptotic pathways in a cisplatin‑induced rat model.Molecular medicine reports · 2016Article
- The Green Tea Polyphenol(-)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease.Journal of translational internal medicine · 2016Review
- Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer.Scientific reports · 2016Article
- Plant-Derived Agents for Counteracting Cisplatin-Induced Nephrotoxicity.Oxidative medicine and cellular longevity · 2016Review
- Epigallocatechin-3-gallate protects against cisplatin-induced nephrotoxicity by inhibiting endoplasmic reticulum stress-induced apoptosis.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- Loss of α(E)-catenin promotes Fas mediated apoptosis in tubular epithelial cells.Apoptosis : an international journal on programmed cell death · 2015Article
- Protective effect of curcumin against experimentally induced aflatoxicosis on the renal cortex of adult male albino rats: a histological and immunohisochemical study.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin (CP) is a commonly used anticancer drug, but its notable side effect of nephrotoxicity limits its use in clinic. Epigallocatechin-3-gallate (EGCG), an anti-oxidant, anti-inflammatory, and anti-tumorigenic green tea polyphenol, has been available on the market for its beneficial effects. The aim of this study was to investigate whether EGCG can prevent the nephrotoxic effect of CP and the involved mechanisms. Male C57/BL6 mice were randomly divided into four groups: control group, EGCG group, CP group, and CP+EGCG group. On day 5, mice were sacrificed. Our results showed that EGCG treatment significantly ameliorated the histopathological changes and the increased serum creatinine and blood urea nitrogen (BUN) induced by CP. TUNEL-positive cells significantly reduced in the CP+EGCG group compared with CP group. EGCG also inhibited the expression of the ligand of death receptor Fas (Fas-L), apoptosis regulator BAX (Bax) and tumor-suppressor protein p53, and increased the expression of B-cell lymphoma 2 (Bcl-2). These findings suggest that EGCG can ameliorate CP-induced apoptosis in the kidney by regulating death receptor Fas conducted extrinsic pathway, and the expression of Bax and Bcl-2.
Indexed as
Identifiers
25197333PMC4152023W2211842933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.